Next Article in Journal
Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
Next Article in Special Issue
Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty
Previous Article in Journal
Alteration of Postural Balance in Patients with Fibromyalgia Syndrome—A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Echocardiography for the Assessment of Pulmonary Hypertension and Congenital Heart Disease in the Young
Communication

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City

Department of Medicine, Pulmonary Critical Care and Sleep Division, New York University Grossman School of Medicine, New York University Langone Health, 462 1st Avenue CD 676, New York, NY 10016, USA
*
Author to whom correspondence should be addressed.
Diagnostics 2021, 11(1), 128; https://doi.org/10.3390/diagnostics11010128
Received: 13 December 2020 / Revised: 11 January 2021 / Accepted: 13 January 2021 / Published: 15 January 2021
(This article belongs to the Special Issue Pulmonary Hypertension: Diagnosis and Management)
Information on outcomes of COVID-19 in pulmonary arterial hypertension (PAH) patients is limited to a few case series and surveys. Here, we describe our experience at a large Pulmonary Hypertension Center in New York City at the height of the pandemic. We performed a retrospective chart review of eleven consecutive PAH patients who were diagnosed with SARS-CoV-2 infection. We analyzed demographics, PAH severity, risk factors for COVID-19, and COVID-19 severity and outcomes. We found in our sample that 63.6% of patients required intensive care, and there was a 45.45% overall mortality. Most patients had a known COVID-19 contact and mean duration of symptoms prior to presentation was 12 days. Only 4/11 (36%) patients presented to a center with pulmonary hypertension expertise, all of whom survived. Most patients had at least moderate pulmonary hypertension with an average REVEAL score of 7.81 despite double or triple PAH therapy. Our cases series underscores the gravity of SARS-CoV-2 infection in patients with PAH. It also suggests possible interventions to prevent unfavorable outcomes such as preserving social distancing, PAH management optimization, and early and preferential presentation to a center with specialized expertise in PAH. View Full-Text
Keywords: pulmonary arterial hypertension; COVID-19; SARS-CoV-2; clinical outcomes pulmonary arterial hypertension; COVID-19; SARS-CoV-2; clinical outcomes
MDPI and ACS Style

Sulica, R.; Cefali, F.; Motschwiller, C.; Fenton, R.; Barroso, A.; Sterman, D. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics 2021, 11, 128. https://doi.org/10.3390/diagnostics11010128

AMA Style

Sulica R, Cefali F, Motschwiller C, Fenton R, Barroso A, Sterman D. COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City. Diagnostics. 2021; 11(1):128. https://doi.org/10.3390/diagnostics11010128

Chicago/Turabian Style

Sulica, Roxana, Frank Cefali, Caroline Motschwiller, Rebecca Fenton, Anabela Barroso, and Daniel Sterman. 2021. "COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City" Diagnostics 11, no. 1: 128. https://doi.org/10.3390/diagnostics11010128

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop